Somnomed Limited (AU:SOM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
SomnoMed Limited has undergone significant changes with the appointment of co-CEOs Karen Borg and Amrita Blickstead, who have driven growth and operational improvements. The company reported FY24 revenue of $91.7 million and has focused on strengthening its manufacturing capabilities to meet rising product demand. With recent FDA clearance of its innovative Rest Assure® device, SomnoMed aims for continued growth and improved financial stability.
For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.
